Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8736977 | Current Opinion in Immunology | 2018 | 8 Pages |
Abstract
Vaccination remains the most cost-effective public health intervention after clean water, and the benefits impressively outweigh the costs. The efforts needed to fulfill the steadily growing demands for next-generation and novel vaccines designed for emerging pathogens and new indications are only realizable in a sustainable business model. Vaccine development can be fast-tracked through strengthening international collaborations, and the continuous innovation of technologies to accelerate their design, development, and manufacturing. However, these processes should be supported by a balanced project portfolio, and by managing sustainable vaccine procurement strategies for different types of markets. Collectively this will allow a gradual shift to a more streamlined and profitable vaccine production, which can significantly contribute to the worldwide effort to shape global health.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Rino Rappuoli, Emmanuel Hanon,